Researchers Find Promise In HIV 'Switch'
Main Category: HIV / AIDSAlso Included In: Genetics; Biology / Biochemistry
Article Date: 18 Mar 2008 - 2:00 PDT
| Patient / Public: | ![]() |
3.5 (2 votes) |
| Healthcare Prof: | ![]() |
If the battle against HIV, the virus that causes AIDS, is a chess match, then new research gives new insight into one of the virus' most important moves.
The findings, by University of Tennessee, Knoxville, and Oak Ridge National Laboratory researchers Michael Simpson and Roy Dar, with colleague Leor Weinberger who led the research at the University of California, San Diego, reveal new information about how a critical genetic switch in the virus operates. They are published as a letter in the upcoming issue of Nature Genetics.
When HIV infects an immune cell, it can enter one of two states: activation, where the virus replicates and then destroys the host cell; and latency, where the viral genetic material continues to exist in the cell, but there is no production of additional virus.
"While latency is a ticking time bomb," said Simpson, "a possible therapeutic goal could be to stably maintain latency indefinitely."
Previous work by Weinberger found that the genetic circuit that controls whether HIV chooses to go active or latent is not a simple "on-off" switch, but instead is controlled by a type of genetic pulse -- when the pulse lasts a certain amount of time, the switch will activate replication of the virus.
Now the three researchers have demonstrated that it is possible to manipulate the lengths of the pulses in a way that would favor the selection of latency.
This is vital, said Simpson, because the switch is a definitive factor in whether the virus will become active. If the pulse does not last long enough, he said, the virus cannot become active.
"This is an early step, but an encouraging one," said Simpson. "HIV has evolved a very effective infection strategy, so the name of the game is understanding how that strategy operates in order to find a way to defeat it."
A challenge of the work, according to Simpson, is that the process involved in how the switch operates cannot be directly observed. Instead, the researchers had to rely on an analysis of the "noise" created within the cell by the process to determine how it worked.
Simpson and Dar conducted their work in the Center for Nanophase Materials Science at ORNL, a recently opened facility that Simpson says has made this type of analysis possible.
Moving forward, the next step in the research is to determine whether it is viable to attempt to control the switch as part of therapeutic treatment for HIV. The researchers also hope to apply the techniques they used to understanding the operation of other types of human cells.
###
The article is available online at http://www.nature.com/ng/journal/vaop/ncurrent/full/ng.116.html.
Source: Jay Mayfield
University of Tennessee
Visit our hiv / aids section for the latest news on this subject.
MLA
13 Feb. 2012. <http://www.medicalnewstoday.com/releases/100925.php>
APA
http://www.medicalnewstoday.com/releases/100925.php.
Please note: If no author information is provided, the source is cited instead.
|
Rate this article: (Hover over the stars then click to rate) |
Patient / Public: |
or |
Health Professional: |
Add Your Opinion
Please note that we publish your name, but we do not publish your email address. It is only used to let you know when your message is published. We do not use it for any other purpose. Please see our privacy policy for more information.
If you write about specific medications or operations, please do not name health care professionals by name.
All opinions are moderated before being included (to stop spam)
Contact Our News Editors
For any corrections of factual information, or to contact the editors please use our feedback form.
![]()
Please send any medical news or health news press releases to:
Note: Any medical information published on this website is not intended as a substitute for informed medical advice and you should not take any action before consulting with a health care professional. For more information, please read our terms and conditions.




